n(g),n(g')-dimethyl-l-arginine has been researched along with Disease Exacerbation in 53 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS." | 8.12 | Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis. ( Aguirre, C; Atsuta, N; Baba, K; Hotta, Y; Ikenaka, K; Ito, D; Kakuda, K; Katsuno, M; Kimura, K; Kimura, Y; Maeda, Y; Mochizuki, H; Nagano, S; Sobue, G; Tatebe, H; Tokuda, T; Torii, R; Yamada, S, 2022) |
| "To evaluate the sequential trend of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in pregnancies developing preeclampsia (PE) as compared to healthy pregnancy (HP) and to estimate their predictive value for development of PE later in pregnancy." | 7.88 | Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia. ( Deepak, KK; Garg, P; Jaryal, AK; Kachhawa, G; Kriplani, A, 2018) |
| " The aim of this study was to evaluate early change in BP and its relation to insulin resistance (IR) and asymmetric dimethylarginine (ADMA)." | 7.83 | Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Marcovecchio, ML; Mohn, A, 2016) |
| "Elevated cerebrospinal fluid (CSF) concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been found in patients with subarachnoid hemorrhage (SAH)." | 7.80 | Increased cerebrospinal fluid concentrations of asymmetric dimethylarginine correlate with adverse clinical outcome in subarachnoid hemorrhage patients. ( Hang, CH; Li, H; Liu, M; Ni, L; Wu, W; Zhang, QR; Zhang, X, 2014) |
| "Dysregulated arginine metabolism was observed in advanced decompensated heart failure, particularly with pulmonary hypertension and elevated intracardiac filling pressures." | 7.78 | Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. ( Borowski, AG; Hazen, SL; Moravec, CS; Shao, Z; Shrestha, K; Sweet, W; Tang, WH; Thakur, A; Thomas, JD; Wang, Z, 2012) |
| "During the acute phase of inflammation/infection, patients displayed very high levels of C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin and nitrotyrosine." | 7.74 | Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. ( Boger, R; Cambareri, F; Cutrupi, S; Enia, G; Finocchiaro, P; Maas, R; Martorano, C; Panuccio, V; Pizzini, P; Schulze, F; Tripepi, G; Zoccali, C, 2007) |
| "We measured plasma levels of ADMA and related compounds, nitrate+nitrite (NO(x)), total homocysteine (tHCY) and assessed renal function and lipid profiles in 145 patients--75 with triple vessel coronary disease and 70 with no detectable coronary disease." | 7.73 | Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. ( Naidoo, D; Salonikas, C; Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2006) |
| "Treatment with ramipril significantly reduced AV(BS) and improved aortic valve :outflow tract flow velocity ratio." | 5.37 | Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. ( Horowitz, JD; Kelly, DJ; Kennedy, JA; Ngo, DT; Qi, W; Smith, MD; Stafford, I; Sverdlov, AL; Weedon, H; Wuttke, RD; Zhang, Y, 2011) |
| "We previously showed that treatment with folic acid (FA)/B12 was associated with more rapid progression of coronary artery disease (CAD)." | 5.17 | The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. ( Bleie, O; Borgeraas, H; Løland, KH; Nordrehaug, JE; Nygård, O; Strand, E; Svardal, A; Ueland, PM, 2013) |
| "The aim was to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS." | 4.12 | Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis. ( Aguirre, C; Atsuta, N; Baba, K; Hotta, Y; Ikenaka, K; Ito, D; Kakuda, K; Katsuno, M; Kimura, K; Kimura, Y; Maeda, Y; Mochizuki, H; Nagano, S; Sobue, G; Tatebe, H; Tokuda, T; Torii, R; Yamada, S, 2022) |
| "To evaluate the sequential trend of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in pregnancies developing preeclampsia (PE) as compared to healthy pregnancy (HP) and to estimate their predictive value for development of PE later in pregnancy." | 3.88 | Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia. ( Deepak, KK; Garg, P; Jaryal, AK; Kachhawa, G; Kriplani, A, 2018) |
| " The aim of this study was to evaluate early change in BP and its relation to insulin resistance (IR) and asymmetric dimethylarginine (ADMA)." | 3.83 | Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. ( Chiarelli, F; Chiavaroli, V; de Giorgis, T; Giannini, C; Marcovecchio, ML; Mohn, A, 2016) |
| "Elevated cerebrospinal fluid (CSF) concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been found in patients with subarachnoid hemorrhage (SAH)." | 3.80 | Increased cerebrospinal fluid concentrations of asymmetric dimethylarginine correlate with adverse clinical outcome in subarachnoid hemorrhage patients. ( Hang, CH; Li, H; Liu, M; Ni, L; Wu, W; Zhang, QR; Zhang, X, 2014) |
| "Dysregulated arginine metabolism was observed in advanced decompensated heart failure, particularly with pulmonary hypertension and elevated intracardiac filling pressures." | 3.78 | Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. ( Borowski, AG; Hazen, SL; Moravec, CS; Shao, Z; Shrestha, K; Sweet, W; Tang, WH; Thakur, A; Thomas, JD; Wang, Z, 2012) |
| " We explored the temporal progression of bile duct ligation (BDL)-induced cholestasis in developing rats, focusing on brain cognition and liver and kidney pathology, to elucidate whether these findings were associated with asymmetric dimethylarginine and oxidative stress alterations." | 3.76 | Bile duct ligation in developing rats: temporal progression of liver, kidney, and brain damage. ( Chen, CC; Hsieh, CS; Huang, LT; Sheen, JM; Tain, YL; Wang, JY, 2010) |
| "This study was designed to determine the relationship between plasma asymmetric dimethylarginine (ADMA) and the development of carotid atherosclerosis." | 3.74 | Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. ( Adachi, H; Enomoto, M; Fukami, A; Furuki, K; Imaizumi, T; Kakuma, T; Kumagae, S; Matsuoka, H; Nanjo, Y; Otsuka, M, 2008) |
| "During the acute phase of inflammation/infection, patients displayed very high levels of C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin and nitrotyrosine." | 3.74 | Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. ( Boger, R; Cambareri, F; Cutrupi, S; Enia, G; Finocchiaro, P; Maas, R; Martorano, C; Panuccio, V; Pizzini, P; Schulze, F; Tripepi, G; Zoccali, C, 2007) |
| "We measured plasma levels of ADMA and related compounds, nitrate+nitrite (NO(x)), total homocysteine (tHCY) and assessed renal function and lipid profiles in 145 patients--75 with triple vessel coronary disease and 70 with no detectable coronary disease." | 3.73 | Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. ( Naidoo, D; Salonikas, C; Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2006) |
| " Covariates that were considered for adjustment included clinical characteristics, baseline GFR (Modification of Diet in Renal Disease equation 7 formula), proteinuria, traditional cardiovascular risk factors, serum C-reactive protein, homocysteine, and concomitant therapies." | 3.73 | Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. ( Malberti, F; Mallamaci, F; Ravani, P; Testa, S; Tripepi, G; Zoccali, C, 2005) |
| "The rationale of this study is based on the fact that, both proteinuria and elevated asymmetric dimethyl arginine (ADMA) levels have been linked to the progression of vascular disease." | 3.73 | ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. ( Acikel, C; Bilgi, C; Caglar, K; Cakir, E; Eyileten, T; Kaya, A; Oguz, Y; Oktenli, C; Sonmez, A; Vural, A; Yenicesu, M; Yilmaz, MI; Zoccali, C, 2006) |
| "Thus, subjects with chronic renal failure are exposed to increased morbidity and mortality from cardiovascular events." | 2.44 | Cardiac biomarkers and chronic renal diseases. ( Kristofova, B; Valocik, G; Valocikova, I, 2008) |
| "Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid that reduces the bioavailability of nitric oxide." | 2.44 | Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. ( Kielstein, JT; Zoccali, C, 2008) |
| "The major feature of COPD is a progressive airflow limitation caused by chronic airway inflammation and consequent airway remodeling." | 1.46 | Positive correlation of airway resistance and serum asymmetric dimethylarginine level in COPD patients with systemic markers of low-grade inflammation. ( Fodor, A; Gesztelyi, R; Keki, S; Mikaczo, A; Pak, K; Papp, C; Szilasi, M; Szilasi, ME; Tajti, G; Zsuga, J, 2017) |
| "Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk." | 1.46 | ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy. ( Bode-Böger, SM; Brilloff, S; Heinrich, A; Hohenstein, B; Hugo, CPM; Jarzebska, N; Martens-Lobenhoffer, J; Rodionov, RN; Todorov, VT; Weiss, N, 2017) |
| " Since disturbed NO bioavailability is a major pathway whereby high uric may cause renal damage, we tested the interaction between the major endogenous inhibitor of NO synthase, asymmetric-dimethylargine (ADMA), and the rs734553 polymorphism for CKD progression in the same cohort." | 1.42 | Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. ( Leonardis, D; Mallamaci, F; Pisano, A; Sanguedolce, MC; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2015) |
| "We recruited 26 ADPKD patients (Group A) with modestly impaired renal function (eGFR 45-70 ml/min/1." | 1.39 | Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. ( Georgianos, PI; Grekas, DM; Kapoulas, S; Makedou, A; Makedou, K; Raptis, V; Sarafidis, PA; Sioulis, A, 2013) |
| "A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline." | 1.38 | ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. ( Bartáková, V; Bělobrádková, J; Jurajda, M; Kaňková, K; Klepárník, M; Krusová, D; Kuricová, K; Malúšková, D; Mužík, J; Olšovský, J; Pácal, L; Pavlík, T; Rehořová, J; Stěpánková, S; Svojanovský, J; Tanhäuserová, V; Tomandl, J, 2012) |
| "Treatment with ramipril significantly reduced AV(BS) and improved aortic valve :outflow tract flow velocity ratio." | 1.37 | Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. ( Horowitz, JD; Kelly, DJ; Kennedy, JA; Ngo, DT; Qi, W; Smith, MD; Stafford, I; Sverdlov, AL; Weedon, H; Wuttke, RD; Zhang, Y, 2011) |
| "Aortic sclerosis is associated with platelet NO resistance rather than conventional coronary risk factors: this might explain the increased thrombotic risk in ASc." | 1.35 | Determinants of occurrence of aortic sclerosis in an aging population. ( Chirkov, YY; Horowitz, JD; McNeil, JJ; Ngo, DT; Nightingale, AK; Sverdlov, AL; Willoughby, SR, 2009) |
| "Reduced bioavailability of nitric oxide (NO) is thought to play an important role in progression of renal damage." | 1.33 | Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. ( Bode-Böger, SM; Fliser, D; Haller, H; Kielstein, JT; Kronenberg, F; Morath, C; Ritz, E, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.89) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 30 (56.60) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Ikenaka, K | 1 |
| Maeda, Y | 1 |
| Hotta, Y | 1 |
| Nagano, S | 1 |
| Yamada, S | 1 |
| Ito, D | 1 |
| Torii, R | 1 |
| Kakuda, K | 1 |
| Tatebe, H | 1 |
| Atsuta, N | 1 |
| Aguirre, C | 1 |
| Kimura, Y | 1 |
| Baba, K | 1 |
| Tokuda, T | 1 |
| Katsuno, M | 1 |
| Kimura, K | 1 |
| Sobue, G | 1 |
| Mochizuki, H | 1 |
| Haşimi, A | 1 |
| Doğan, Ö | 1 |
| Serdar, CC | 1 |
| Serdar, MA | 1 |
| Büttner, P | 1 |
| Bahls, M | 1 |
| Böger, RH | 2 |
| Hindricks, G | 1 |
| Thiele, H | 1 |
| Schwedhelm, E | 1 |
| Kornej, J | 1 |
| Tajti, G | 1 |
| Gesztelyi, R | 1 |
| Pak, K | 1 |
| Papp, C | 1 |
| Keki, S | 1 |
| Szilasi, ME | 1 |
| Mikaczo, A | 1 |
| Fodor, A | 1 |
| Szilasi, M | 1 |
| Zsuga, J | 1 |
| Vögeli, A | 1 |
| Ottiger, M | 1 |
| Meier, MA | 1 |
| Steuer, C | 1 |
| Bernasconi, L | 1 |
| Huber, A | 1 |
| Christ-Crain, M | 1 |
| Henzen, C | 1 |
| Hoess, C | 1 |
| Thomann, R | 1 |
| Zimmerli, W | 1 |
| Mueller, B | 1 |
| Schuetz, P | 1 |
| Rodionov, RN | 1 |
| Heinrich, A | 1 |
| Brilloff, S | 1 |
| Jarzebska, N | 1 |
| Martens-Lobenhoffer, J | 3 |
| Bode-Böger, SM | 5 |
| Todorov, VT | 1 |
| Hugo, CPM | 1 |
| Weiss, N | 1 |
| Hohenstein, B | 1 |
| Emrich, IE | 1 |
| Zawada, AM | 1 |
| Fliser, D | 4 |
| Wagenpfeil, S | 1 |
| Heine, GH | 1 |
| Garg, P | 1 |
| Jaryal, AK | 1 |
| Kachhawa, G | 1 |
| Deepak, KK | 1 |
| Kriplani, A | 1 |
| Løland, KH | 1 |
| Bleie, O | 1 |
| Borgeraas, H | 1 |
| Strand, E | 1 |
| Ueland, PM | 1 |
| Svardal, A | 1 |
| Nordrehaug, JE | 1 |
| Nygård, O | 1 |
| Žižek, B | 1 |
| Žižek, D | 1 |
| Bedenčič, K | 1 |
| Jerin, A | 1 |
| Poredoš, P | 1 |
| Raptis, V | 1 |
| Georgianos, PI | 1 |
| Sarafidis, PA | 1 |
| Sioulis, A | 1 |
| Makedou, K | 1 |
| Makedou, A | 1 |
| Grekas, DM | 1 |
| Kapoulas, S | 1 |
| Ali, OA | 1 |
| Chapman, M | 1 |
| Nguyen, TH | 1 |
| Chirkov, YY | 2 |
| Heresztyn, T | 1 |
| Mundisugih, J | 1 |
| Horowitz, JD | 3 |
| Li, H | 1 |
| Wu, W | 1 |
| Liu, M | 1 |
| Zhang, X | 1 |
| Zhang, QR | 1 |
| Ni, L | 1 |
| Hang, CH | 1 |
| Eiselt, J | 1 |
| Rajdl, D | 1 |
| Racek, J | 1 |
| Vostrý, M | 1 |
| Rulcová, K | 1 |
| Wirth, J | 1 |
| Tripepi, G | 5 |
| Kollerits, B | 1 |
| Leonardis, D | 2 |
| Yilmaz, MI | 2 |
| Postorino, M | 1 |
| Mallamaci, F | 3 |
| Kronenberg, F | 2 |
| Zoccali, C | 9 |
| Sandoo, A | 1 |
| Dimitroulas, T | 1 |
| Hodson, J | 1 |
| Smith, JP | 1 |
| Douglas, KM | 1 |
| Kitas, GD | 1 |
| Testa, A | 1 |
| Spoto, B | 1 |
| Pisano, A | 1 |
| Sanguedolce, MC | 1 |
| Aydin, M | 1 |
| Altintas, N | 1 |
| Cem Mutlu, L | 1 |
| Bilir, B | 1 |
| Oran, M | 1 |
| Tülübaş, F | 1 |
| Topçu, B | 1 |
| Tayfur, İ | 1 |
| Küçükyalçin, V | 1 |
| Kaplan, G | 1 |
| Gürel, A | 1 |
| de Giorgis, T | 1 |
| Marcovecchio, ML | 1 |
| Giannini, C | 1 |
| Chiavaroli, V | 1 |
| Chiarelli, F | 1 |
| Mohn, A | 1 |
| Aldámiz-Echevarria, L | 2 |
| Andrade, F | 2 |
| Llarena, M | 1 |
| de Las Heras, J | 1 |
| Couce, ML | 1 |
| Lucca, F | 1 |
| Da Dalt, L | 1 |
| Ros, M | 1 |
| Gucciardi, A | 1 |
| Pirillo, P | 1 |
| Naturale, M | 1 |
| Perilongo, G | 1 |
| Giordano, G | 1 |
| Baraldi, E | 1 |
| Parrish, AR | 1 |
| Furuki, K | 1 |
| Adachi, H | 1 |
| Enomoto, M | 1 |
| Otsuka, M | 1 |
| Fukami, A | 1 |
| Kumagae, S | 1 |
| Matsuoka, H | 2 |
| Nanjo, Y | 1 |
| Kakuma, T | 1 |
| Imaizumi, T | 2 |
| Valocikova, I | 1 |
| Kristofova, B | 1 |
| Valocik, G | 1 |
| Mora-Fernández, C | 1 |
| Jarque, A | 1 |
| Getino, MA | 1 |
| Sánchez, R | 1 |
| Lozano, L | 1 |
| Navarro, JF | 1 |
| Kielstein, JT | 4 |
| Guagnano, MT | 1 |
| Ferroni, P | 1 |
| Santilli, F | 1 |
| Paoletti, V | 1 |
| Manigrasso, MR | 1 |
| Pescara, L | 1 |
| Cuccurullo, C | 1 |
| Ciabattoni, G | 1 |
| Davì, G | 1 |
| Wadham, C | 1 |
| Mangoni, AA | 1 |
| Ayer, JG | 1 |
| Harmer, JA | 1 |
| Nakhla, S | 1 |
| Xuan, W | 1 |
| Ng, MK | 1 |
| Raitakari, OT | 1 |
| Marks, GB | 1 |
| Celermajer, DS | 1 |
| Ngo, DT | 2 |
| Sverdlov, AL | 2 |
| Willoughby, SR | 1 |
| Nightingale, AK | 1 |
| McNeil, JJ | 1 |
| David, S | 1 |
| Kümpers, P | 1 |
| Lukasz, A | 1 |
| Kliem, V | 1 |
| Haller, H | 2 |
| Sheen, JM | 1 |
| Huang, LT | 1 |
| Hsieh, CS | 1 |
| Chen, CC | 1 |
| Wang, JY | 1 |
| Tain, YL | 1 |
| Stafford, I | 1 |
| Qi, W | 1 |
| Wuttke, RD | 1 |
| Zhang, Y | 1 |
| Kelly, DJ | 1 |
| Weedon, H | 1 |
| Smith, MD | 1 |
| Kennedy, JA | 1 |
| Massera, D | 1 |
| Mittermayer, F | 1 |
| Gisslinger, B | 1 |
| Olcaydu, D | 1 |
| Wolzt, M | 1 |
| Gisslinger, H | 1 |
| Lilitkarntakul, P | 1 |
| Dhaun, N | 1 |
| Melville, V | 1 |
| Blackwell, S | 1 |
| Talwar, DK | 1 |
| Liebman, B | 1 |
| Asai, T | 1 |
| Pollock, J | 1 |
| Goddard, J | 1 |
| Webb, DJ | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Ghiadoni, L | 1 |
| Bruno, RM | 1 |
| Mancia, G | 1 |
| Baylis, C | 1 |
| Shao, Z | 1 |
| Wang, Z | 1 |
| Shrestha, K | 1 |
| Thakur, A | 1 |
| Borowski, AG | 1 |
| Sweet, W | 1 |
| Thomas, JD | 1 |
| Moravec, CS | 1 |
| Hazen, SL | 1 |
| Tang, WH | 1 |
| Nicković, V | 1 |
| Nikolić, J | 1 |
| Djindjić, N | 1 |
| Ilić, M | 1 |
| Nicković, J | 1 |
| Mladenović, D | 1 |
| Krstić, N | 1 |
| Tanhäuserová, V | 1 |
| Tomandl, J | 1 |
| Pácal, L | 1 |
| Klepárník, M | 1 |
| Malúšková, D | 1 |
| Bartáková, V | 1 |
| Kuricová, K | 1 |
| Rehořová, J | 1 |
| Stěpánková, S | 1 |
| Svojanovský, J | 1 |
| Olšovský, J | 1 |
| Bělobrádková, J | 1 |
| Krusová, D | 1 |
| Jurajda, M | 1 |
| Mužík, J | 1 |
| Pavlík, T | 1 |
| Kaňková, K | 1 |
| Rajagopalan, S | 1 |
| Pfenninger, D | 1 |
| Kehrer, C | 1 |
| Chakrabarti, A | 1 |
| Somers, E | 1 |
| Pavlic, R | 1 |
| Mukherjee, D | 1 |
| Brook, R | 1 |
| D'Alecy, LG | 1 |
| Kaplan, MJ | 1 |
| Cooke, JP | 2 |
| Morath, C | 1 |
| Ritz, E | 1 |
| Wang, J | 1 |
| Sim, AS | 1 |
| Wang, XL | 1 |
| Salonikas, C | 1 |
| Naidoo, D | 1 |
| Wilcken, DE | 1 |
| Ravani, P | 1 |
| Malberti, F | 1 |
| Testa, S | 1 |
| Caglar, K | 1 |
| Sonmez, A | 1 |
| Cakir, E | 1 |
| Kaya, A | 1 |
| Acikel, C | 1 |
| Eyileten, T | 1 |
| Yenicesu, M | 1 |
| Oguz, Y | 1 |
| Bilgi, C | 1 |
| Oktenli, C | 1 |
| Vural, A | 1 |
| Maas, R | 1 |
| Cutrupi, S | 1 |
| Pizzini, P | 1 |
| Finocchiaro, P | 1 |
| Cambareri, F | 1 |
| Panuccio, V | 1 |
| Martorano, C | 1 |
| Schulze, F | 1 |
| Enia, G | 1 |
| Boger, R | 1 |
| Matsumoto, Y | 1 |
| Ueda, S | 1 |
| Yamagishi, S | 1 |
| Matsuguma, K | 1 |
| Shibata, R | 1 |
| Fukami, K | 1 |
| Okuda, S | 1 |
| Schiffrin, EL | 1 |
| Lipman, ML | 1 |
| Mann, JF | 1 |
| Thiele, W | 1 |
| Junker, W | 1 |
| Alexander, K | 1 |
| Frölich, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967] | Phase 3 | 450 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418] | 102 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792] | Phase 2 | 215 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for n(g),n(g')-dimethyl-l-arginine and Disease Exacerbation
| Article | Year |
|---|---|
The cytoskeleton as a novel target for treatment of renal fibrosis.
Topics: Actins; Animals; Arginine; Cytoskeleton; Disease Progression; Epithelial Cells; Fibrosis; Humans; Ki | 2016 |
Cardiac biomarkers and chronic renal diseases.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Disease Progression; Hom | 2008 |
[Novelties in the field of progression factors in chronic kidney disease].
Topics: Adult; Amidohydrolases; Animals; Arginine; Carbon; Cardiovascular Diseases; Chronic Disease; Clinica | 2008 |
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chronic Disease; Disease Progression; Genetic Therap | 2008 |
Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.
Topics: Amidohydrolases; Animals; Arginine; Cardiovascular Agents; Cardiovascular Diseases; Disease Progress | 2009 |
Nitric oxide synthase derangements and hypertension in kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Chronic Disease; Disease Progression; Humans; Hypertension; Kidn | 2012 |
Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
Topics: Adult; Amidohydrolases; Arginine; Biomarkers; Cardiovascular Diseases; Child; Disease Progression; E | 2012 |
The pivotal role of nitric oxide for vascular health.
Topics: Arginine; Arteriosclerosis; Cardiovascular Diseases; Disease Progression; Endothelium, Vascular; Fem | 2004 |
Biomarkers in chronic kidney disease: utility and issues towards better understanding.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Chronic Disease; Disease Progression; Glomerular | 2005 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Disease Exacerbation
| Article | Year |
|---|---|
The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine.
Topics: Adenosine; Aged; Arginine; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ethio | 2013 |
42 other studies available for n(g),n(g')-dimethyl-l-arginine and Disease Exacerbation
| Article | Year |
|---|---|
Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Arginine; Biomarkers; Disease Progression; Humans; Nitric Oxide; Prog | 2022 |
Association of serum ADMA, SDMA and L-NMMA concentrations with disease progression in COVID-19 patients.
Topics: Arginine; COVID-19; Disease Progression; Humans; omega-N-Methylarginine | 2023 |
Arginine derivatives in atrial fibrillation progression phenotypes.
Topics: Aged; Arginine; Atrial Fibrillation; Biomarkers; Cohort Studies; Disease Progression; Female; Homoar | 2020 |
Positive correlation of airway resistance and serum asymmetric dimethylarginine level in COPD patients with systemic markers of low-grade inflammation.
Topics: Aged; Airway Resistance; Arginine; Biomarkers; Bronchodilator Agents; C-Reactive Protein; Chi-Square | 2017 |
Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Disease Progression; Female; Humans; Male; Middle Age | 2017 |
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Topics: Albuminuria; Amidohydrolases; Animals; Arginine; Cell Proliferation; Creatinine; Diabetes Mellitus, | 2017 |
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Chromatography, Liquid; Disease Progression; Fe | 2018 |
Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Disease Progression; Female; | 2018 |
Effect of metabolic abnormalities on endothelial dysfunction in normotensive offspring of subject with hypertension.
Topics: Adiponectin; Adult; Arginine; Biomarkers; Brachial Artery; Case-Control Studies; Disease Progression | 2013 |
Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Aged; Arginine; Dinoprost; Disease Progression; Female; Glomerular Filtration Rat | 2013 |
Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve.
Topics: Aorta; Aortic Valve; Arginine; Bicuspid Aortic Valve Disease; Biomarkers; Disease Progression; Echoc | 2014 |
Increased cerebrospinal fluid concentrations of asymmetric dimethylarginine correlate with adverse clinical outcome in subarachnoid hemorrhage patients.
Topics: Adult; Aged; Arginine; Chromatography, High Pressure Liquid; Disease Progression; Female; Follow-Up | 2014 |
Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
Topics: Advanced Oxidation Protein Products; Aged; Arginine; Biomarkers; Case-Control Studies; Disease Progr | 2014 |
Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.
Topics: Adult; Aged; Arginine; Cohort Studies; Disease Progression; Female; Fibroblast Growth Factor-23; Fib | 2015 |
Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study.
Topics: Aged; Arginine; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cardiova | 2015 |
Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Topics: Aged; Alleles; Arginine; C-Reactive Protein; Calcium; Case-Control Studies; Cohort Studies; Creatini | 2015 |
Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD.
Topics: Aged; Arginine; Biomarkers; Cross-Sectional Studies; Disease Progression; Enzyme Inhibitors; Enzyme- | 2017 |
Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine.
Topics: Adolescent; Adolescent Development; Arginine; Biomarkers; Blood Pressure Monitoring, Ambulatory; Bod | 2016 |
Dimethylarginines as biomarkers for the kidney transplant management in methylmalonic aciduria.
Topics: Adult; Allografts; Amino Acid Metabolism, Inborn Errors; Arginine; Biomarkers; Cause of Death; Disea | 2015 |
Asymmetric dimethylarginine and related metabolites in exhaled breath condensate of children with cystic fibrosis.
Topics: Adolescent; Arginine; Biomarkers; Breath Tests; Child; Chromatography, High Pressure Liquid; Cystic | 2018 |
Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography.
Topics: Aged; Arginine; Atherosclerosis; Carotid Arteries; Disease Progression; Female; Humans; Linear Model | 2008 |
Determinants of platelet activation in hypertensives with microalbuminuria.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Disease Progression; Endothelium; Female; Humans; Hypertens | 2009 |
HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children.
Topics: Arginine; Biomarkers; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Dise | 2009 |
Determinants of occurrence of aortic sclerosis in an aging population.
Topics: Age Factors; Aged; Aorta; Aortic Valve; Aortic Valve Stenosis; Arginine; Biomarkers; Blood Platelets | 2009 |
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
Topics: Adult; Aged; Angiopoietin-2; Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Ch | 2010 |
Bile duct ligation in developing rats: temporal progression of liver, kidney, and brain damage.
Topics: Animals; Arginine; Bile Ducts; Brain; Brain Diseases; Cholestasis; Disease Progression; End Stage Li | 2010 |
Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Valve; Aortic Valve Stenosis; Arginine; Ca | 2011 |
Asymmetric dimethylarginine levels in essential thrombocythemia--a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Body Mass Index; Cohort Studies; Disease Progression; Huma | 2011 |
Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Blood Pressure; Brachial Artery; C-Reactive Prote | 2011 |
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Chronic Disease; Cross-Sectional Studies; Disease Pro | 2011 |
Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.
Topics: Aged; Amidohydrolases; Arginine; Disease Progression; Female; Heart Failure, Systolic; Humans; Hyper | 2012 |
Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis.
Topics: Adult; Aged; Arginine; Biomarkers; Creatinine; Disease Progression; Hepatorenal Syndrome; Humans; Li | 2012 |
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis.
Topics: Adult; Aged; Amidohydrolases; Arginine; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, | 2012 |
Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.
Topics: Adult; Arginine; Brachial Artery; Chemokine CCL2; Cold Temperature; Disease Progression; Endothelin- | 2003 |
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Topics: Adult; Arginine; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Hemoglobins; H | 2005 |
Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease.
Topics: Adult; Aged; Arginine; Biomarkers; Chromatography, High Pressure Liquid; Coronary Angiography; Coron | 2006 |
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular System; Cohort Studies; Dialysis; Dis | 2005 |
ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Chronic Disease; Disease Prog | 2006 |
Letter by Kielstein et al regarding article, "Renal function as a predictor of outcome in a broad spectrum of patients with heart failure".
Topics: Angiotensin-Converting Enzyme Inhibitors; Arginine; Cardiac Output, Low; Creatinine; Disease Progres | 2006 |
Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections.
Topics: Acute Disease; Arginine; Bacterial Infections; Biomarkers; Blood Pressure; C-Reactive Protein; Calci | 2007 |
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Capillaries; Chronic Disease; Disease Models, Animal; Disease Pr | 2007 |
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arginine; Arterial Occlusive Diseases; Cyclic GMP; Disease Pr | 1997 |